548 Phase 2 study of FLX475 in combination with ipilimumab in advanced melanoma von Goyal, Rakesh, Nasrah, Nicole, Johnson, Dan, Ho, William

Volltext

629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoin... von Kim, Tae Min, Ngamphaiboon, Nuttapong, Lee, Ki Hyeong, Desai, Pratibha, Lin, Chia-Chi, Muzaffar, Jameel, Feng, Yin-Hsun, Wu, Shang-Yin, Brahmer, Julie, Chisamore, Michael, Kassner, Paul D, Brockstedt, Dirk G, Goyal, Rakesh Kumar, Nasrah, Nicole, Ho, William

Volltext

Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer von Ho, William, Nasrah, Nicole, Johnson, Dan

Volltext

Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer von Powderly, John D., Chmielowski, Bartosz, Brahmer, Julie R., Piha-Paul, Sarina Anne, Bowyer, Samantha Elizabeth, LoRusso, Patricia, Catenacci, Daniel V.T., Wu, Christina, Barve, Minal A., Chisamore, Michael Jon, Nasrah, Nicole, Johnson, Dan, Ho, William

Volltext